BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1736 related articles for article (PubMed ID: 15990009)

  • 21. Correlation between saliva production and quality of life measurements in head and neck cancer patients treated with intensity-modulated radiotherapy.
    Scrimger R; Kanji A; Parliament M; Warkentin H; Field C; Jha N; Hanson J
    Am J Clin Oncol; 2007 Jun; 30(3):271-7. PubMed ID: 17551304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three-dimensional conformal radiotherapy for locally advanced (Stage II and worse) head-and-neck cancer: dosimetric and clinical evaluation.
    Portaluri M; Fucilli FI; Castagna R; Bambace S; Pili G; Tramacere F; Russo D; Francavilla MC
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1036-43. PubMed ID: 16750321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of NTCP models for head and neck cancer patients treated with three-dimensional conformal radiotherapy for xerostomia and sticky saliva: the role of dosimetric and clinical factors.
    Beetz I; Schilstra C; Burlage FR; Koken PW; Doornaert P; Bijl HP; Chouvalova O; Leemans CR; de Bock GH; Christianen ME; van der Laan BF; Vissink A; Steenbakkers RJ; Langendijk JA
    Radiother Oncol; 2012 Oct; 105(1):86-93. PubMed ID: 21632133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does radiation dose to the salivary glands and oral cavity predict patient-rated xerostomia and sticky saliva in head and neck cancer patients treated with curative radiotherapy?
    Jellema AP; Doornaert P; Slotman BJ; Leemans CR; Langendijk JA
    Radiother Oncol; 2005 Nov; 77(2):164-71. PubMed ID: 16256229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function.
    Kwong DL; Pow EH; Sham JS; McMillan AS; Leung LH; Leung WK; Chua DT; Cheng AC; Wu PM; Au GK
    Cancer; 2004 Oct; 101(7):1584-93. PubMed ID: 15378492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recurrences after conformal parotid-sparing radiotherapy for head and neck cancer.
    Bussels B; Maes A; Hermans R; Nuyts S; Weltens C; Van den Bogaert W
    Radiother Oncol; 2004 Aug; 72(2):119-27. PubMed ID: 15297131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy.
    Li Y; Taylor JM; Ten Haken RK; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):660-9. PubMed ID: 17141973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program.
    Vergeer MR; Doornaert PA; Rietveld DH; Leemans CR; Slotman BJ; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):1-8. PubMed ID: 19111400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors influencing the parotid function in nasopharyngeal carcinoma treated with parotid-sparing radiotherapy.
    Liu WS; Lee SP; Lee JK; Su MC; Chen GD; Lee HS; Lee H
    Jpn J Clin Oncol; 2006 Oct; 36(10):626-31. PubMed ID: 17008345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intensity-modulated radiation therapy and xerostomia.
    Chambers MS; Weber RS; Garden AS
    J Calif Dent Assoc; 2006 Sep; 34(9):743-8. PubMed ID: 17022299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report.
    Jabbari S; Kim HM; Feng M; Lin A; Tsien C; Elshaikh M; Terrel JE; Murdoch-Kinch C; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):725-31. PubMed ID: 16199308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NTCP models for patient-rated xerostomia and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer: the role of dosimetric and clinical factors.
    Beetz I; Schilstra C; van der Schaaf A; van den Heuvel ER; Doornaert P; van Luijk P; Vissink A; van der Laan BF; Leemans CR; Bijl HP; Christianen ME; Steenbakkers RJ; Langendijk JA
    Radiother Oncol; 2012 Oct; 105(1):101-6. PubMed ID: 22516776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality of life and salivary output in patients with head-and-neck cancer five years after radiotherapy.
    Braam PM; Roesink JM; Raaijmakers CP; Busschers WB; Terhaard CH
    Radiat Oncol; 2007 Jan; 2():3. PubMed ID: 17207274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Scintigraphic assessment of salivary function after intensity-modulated radiotherapy for head and neck cancer: correlations with parotid dose and quality of life.
    Chen WC; Lai CH; Lee TF; Hung CH; Liu KC; Tsai MF; Wang WH; Chen H; Fang FM; Chen MF
    Oral Oncol; 2013 Jan; 49(1):42-8. PubMed ID: 22854066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Importance of the initial volume of parotid glands in xerostomia for patients with head and neck cancers treated with IMRT.
    Nishimura Y; Nakamatsu K; Shibata T; Kanamori S; Koike R; Okumura M; Suzuki M
    Jpn J Clin Oncol; 2005 Jul; 35(7):375-9. PubMed ID: 15976068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer.
    Eisbruch A; Ship JA; Dawson LA; Kim HM; Bradford CR; Terrell JE; Chepeha DB; Teknos TN; Hogikyan ND; Anzai Y; Marsh LH; Ten Haken RK; Wolf GT
    World J Surg; 2003 Jul; 27(7):832-7. PubMed ID: 14509515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Whole saliva physico-biochemical changes and quality of life in head and neck cancer patients following conventional radiation therapy: a prospective longitudinal study.
    Tiwana MS; Mahajan MK; Uppal B; Koshy G; Sachdeva J; Lee HN; Talole SD
    Indian J Cancer; 2011; 48(3):289-95. PubMed ID: 21921325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
    Thorstad WL; Chao KS; Haughey B
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function.
    Saarilahti K; Kouri M; Collan J; Hämäläinen T; Atula T; Joensuu H; Tenhunen M
    Radiother Oncol; 2005 Mar; 74(3):251-8. PubMed ID: 15763305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brachytherapy versus surgery in carcinoma of tonsillar fossa and/or soft palate: late adverse sequelae and performance status: can we be more selective and obtain better tissue sparing?
    Levendag P; Nijdam W; Noever I; Schmitz P; van de Pol M; Sipkema D; Braat C; de Boer M; Jansen P
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):713-24. PubMed ID: 15183475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 87.